Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation

Biochemical and Biophysical Research Communications

Volumn 420, Issue 1, 2012, Pages 29-35

  Xing, Chunyang ^a   Xie, Haiyang ^a   Zhou, Lin ^a   Zhou, Wuhua ^a   Zhang, Wu ^a   Ding, Songming ^a   Wei, Bajin ^a   Yu, Xiaobo ^a   Su, Rong ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

BIRC5; CDKN3; Co expression; Oncomine; P21

Indexed keywords

BIRC5 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 3; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE ASSOCIATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

ADULT; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; YOUNG ADULT;

EID: 84862807310     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.107     Document Type: Article

References (41)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Hannon G.J., Casso D., Beach D. KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA 1994, 91:1731-1735.
3. Gyuris J., Golemis E., Chertkov H., Brent R. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 1993, 75:791-803.
4. Hannon G.J., Casso D., Beach D. Kap - a dual-specificity phosphatase that interacts with cyclin-dependent kinases. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:1731-1735.
5. Johnson L.N., De Moliner E., Brown N.R., Song H., Barford D., Endicott J.A., Noble M.E. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol. Ther. 2002, 93:113-124.
6. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12:2245-2262.
7. Martelli F., Livingston D.M. Regulation of endogenous E2F1 stability by the retinoblastoma family proteins. Proc. Natl. Acad. Sci. USA 1999, 96:2858-2863.
8. Cecchini M.J., Dick F.A. The biochemical basis of CDK phosphorylation-independent regulation of E2F1 by the retinoblastoma protein. Biochem. J. 2011, 434:297-308.
9. Morris E.J., Ji J.Y., Yang F., Di Stefano L., Herr A., Moon N.S., Kwon E.J., Haigis K.M., Naar A.M., Dyson N.J. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 2008, 455:552-556.
10. Okamoto K., Kitabayashi I., Taya Y. KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction. Biochem. Biophys. Res. Commun. 2006, 351:216-222.
11. Lee S.W., Reimer C.L., Fang L., Iruela-Arispe M.L., Aaronson S.A. Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol. Cell Biol. 2000, 20:1723-1732.
12. Yeh C.T., Lu S.C., Chen T.C., Peng C.Y., Liaw Y.F. Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. Cancer Res. 2000, 60:4697-4700.
13. Jiang R., Xia Y., Li J., Deng L., Zhao L., Shi J., Wang X., Sun B. High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. Int. J. Cancer 2010, 126:1263-1274.
14. Cheng J., Zhou L., Xie Q.F., Xie H.Y., Wei X.Y., Gao F., Xing C.Y., Xu X., Li L.J., Zheng S.S. The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics 2010, 10:1557-1572.
15. Wu L.M., Yang Z., Zhou L., Zhang F., Xie H.Y., Feng X.W., Wu J., Zheng S.S. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 2010, 5:e14460.
16. Cheng J., Xie H.Y., Xu X., Wu J., Wei X., Su R., Zhang W., Lv Z., Zheng S., Zhou L. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011, 310:35-45.
17. Yang Z., Zhou L., Wu L.M., Lai M.C., Xie H.Y., Zhang F., Zheng S.S. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann. Surg. Oncol. 2011, 18:1243-1250.
18. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
19. Wurmbach E., Chen Y.B., Khitrov G., Zhang W., Roayaie S., Schwartz M., Fiel I., Thung S., Mazzaferro V., Bruix J., Bottinger E., Friedman S., Waxman S., Llovet J.M. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007, 45:938-947.
20. Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., Lai K.M., Ji J., Dudoit S., Ng I.O., Van De Rijn M., Botstein D., Brown P.O. Gene expression patterns in human liver cancers. Mol. Biol. Cell 2002, 13:1929-1939.
21. Roessler S., Jia H.L., Budhu A., Forgues M., Ye Q.H., Lee J.S., Thorgeirsson S.S., Sun Z., Tang Z.Y., Qin L.X., Wang X.W. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010, 70:10202-10212.
22. Mas V.R., Maluf D.G., Archer K.J., Yanek K., Kong X., Kulik L., Freise C.E., Olthoff K.M., Ghobrial R.M., McIver P., Fisher R. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol. Med. 2009, 15:85-94.
23. Fierro A.C., Vandenbussche F., Engelen K., Van de Peer Y., Marchal K. Meta analysis of gene expression data within and across species. Curr. Genomics 2008, 9:525-534.
24. Kim S.S., Chen Y.M., O'Leary E., Witzgall R., Vidal M., Bonventre J.V. A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins. Proc. Natl. Acad. Sci. USA 1996, 93:15299-15304.
25. Friedman J.R., Fredericks W.J., Jensen D.E., Speicher D.W., Huang X.P., Neilson E.G., Rauscher F.J. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev. 1996, 10:2067-2078.
26. Agata Y., Matsuda E., Shimizu A. Two novel Kruppel-associated box-containing zinc-finger proteins, KRAZ1 and KRAZ2, repress transcription through functional interaction with the corepressor KAP-1 TIF1 beta/KRIP-1. J. Biol. Chem. 1999, 274:16412-16422.
27. Schultz D.C., Ayyanathan K., Negorev D., Maul G.G., Rauscher F.J. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 2002, 16:919-932.
28. Schultz D.C., Friedman J.R., Rauscher F.J. Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD. Genes Dev. 2001, 15:428-443.
29. Underhill C., Qutob M.S., Yee S.P., Torchia J. A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1. J. Biol. Chem. 2000, 275:40463-40470.
30. Niculescu M.D., Yamamuro Y., Zeisel S.H. Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene. J. Neurochem. 2004, 89:1252-1259.
31. Chinami M., Yano Y., Yang X., Salahuddin S., Moriyama K., Shiroishi M., Turner H., Shirakawa T., Adra C.N. Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase (KAP). Cdk2.cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of Cdk2. J. Biol. Chem 2005, 280:17235-17242.
32. Yu Y., Jiang X., Schoch B.S., Carroll R.S., Black P.M., Johnson M.D. Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res. 2007, 67:130-138.
33. Chen J., Jackson P.K., Kirschner M.W., Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995, 374:386-388.
34. Chang B.D., Watanabe K., Broude E.V., Fang J., Poole J.C., Kalinichenko T.V., Roninson I.B. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc. Natl. Acad. Sci. USA 2000, 97:4291-4296.
35. Schafer D.F., Sorrell M.F. Hepatocellular carcinoma. Lancet 1999, 353:1253-1257.
36. Shirabe K., Kanematsu T., Matsumata T., Adachi E., Akazawa K., Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991, 14:802-805.
37. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002, 3:401-410.
38. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3:917-921.
39. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
40. Giodini A., Kallio M.J., Wall N.R., Gorbsky G.J., Tognin S., Marchisio P.C., Symons M., Altieri D.C. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002, 62:2462-2467.
41. Connell C.M., Wheatley S.P., McNeish I.A. Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Res. 2008, 68:7923-7931.